Literature DB >> 11325692

Hyperammonemia in urea cycle disorders: role of the nephrologist.

R S Mathias1, D Kostiner, S Packman.   

Abstract

Hyperammonemia associated with inherited disorders of amino acid and organic acid metabolism is usually manifested by irritability, somnolence, vomiting, seizures, and coma. Although the majority of these patients present in the newborn period, they may also present in childhood, adolescence, and adulthood with failure to thrive, persistent vomiting, developmental delay, or behavioral changes. Persistent hyperammonemia, if not treated rapidly, may cause irreversible neuronal damage. After the diagnosis of hyperammonemia is established in an acutely ill patient, certain diagnostic tests should be performed to differentiate between urea cycle defects and other causes of hyperammonemic encephalopathy. In a patient with a presumed inherited metabolic disorder, the aim of therapy should be to normalize blood ammonia levels. Recent experience has provided treatment guidelines that include minimizing endogenous ammonia production and protein catabolism, restricting nitrogen intake, administering substrates of the urea cycle, administering compounds that facilitate the removal of ammonia through alternative pathways, and, in severe cases, dialysis therapy. Initiation of dialysis in the encephalopathic patient with hyperammonemia is indicated if the ammonia blood level is greater than three to four times the upper limit of normal. Hemodialysis is the most effective treatment for rapidly reducing blood ammonia levels. Continuous hemofiltration and peritoneal dialysis are also effective modalities for reducing blood ammonia levels. An improved understanding of the metabolism of ammonia and neurological consequences of hyperammonemia will assist the nephrologist in providing optimal care for this high-risk patient population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325692     DOI: 10.1016/s0272-6386(05)80026-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  9 in total

Review 1.  Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS--a review of clinical, biochemical, and electrophysiological data.

Authors:  S Mitzner; J Loock; P Peszynski; S Klammt; J Majcher-Peszynska; A Gramowski; J Stange; R Schmidt
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

2.  An infant with hypercalcemia and hyperammonia: inborn error of metabolism or not? Answers.

Authors:  Arife Uslu Gökceoğlu; Medine Ayşin Taşar; Zahide Yalaki; Abdullah Güneş; Abdullatif Bakır
Journal:  Pediatr Nephrol       Date:  2018-07-19       Impact factor: 3.714

3.  Acute treatment of hyperammonemia by continuous renal replacement therapy in a newborn patient with ornithine transcarbamylase deficiency.

Authors:  Hyo Jeong Kim; Se Jin Park; Kook In Park; Jin Sung Lee; Ho Sun Eun; Ji Hong Kim; Jae Il Shin
Journal:  Korean J Pediatr       Date:  2011-10-31

Review 4.  The Role of RRT in Hyperammonemic Patients.

Authors:  Shruti Gupta; Andrew Z Fenves; Robert Hootkins
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-19       Impact factor: 8.237

5.  High-dose continuous renal replacement therapy for neonatal hyperammonemia.

Authors:  Joann M Spinale; Benjamin L Laskin; Neal Sondheimer; Sarah J Swartz; Stuart L Goldstein
Journal:  Pediatr Nephrol       Date:  2013-03-08       Impact factor: 3.714

6.  Hemodialysis for hyperammonemia associated with ornithine transcarbamylase deficiency.

Authors:  Jacob F Collen; Nealanjon P Das; Jonathan M Koff; Robert T Neff; Kevin C Abbott
Journal:  Appl Clin Genet       Date:  2008-07-24

7.  Urea Cycle Disorders.

Authors:  Soledad Kleppe; Asad Mian; Brendan Lee
Journal:  Curr Treat Options Neurol       Date:  2003-07       Impact factor: 3.972

8.  Hyperammonemia in a patient with late-onset ornithine carbamoyltransferase deficiency.

Authors:  Dae Eun Choi; Kang Wook Lee; Young Tai Shin; Ki Ryang Na
Journal:  J Korean Med Sci       Date:  2012-04-25       Impact factor: 2.153

9.  Hyperammonemic Coma in an Adult due to Ornithine Transcarbamylase Deficiency.

Authors:  Daniel L Roberts; David A Galbreath; Bhavesh M Patel; Timothy J Ingall; Amer Khatib; Daniel J Johnson
Journal:  Case Rep Crit Care       Date:  2013-02-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.